The clinical benefit of sunitinib was observed for the most frequent primary GIST genotypes: KIT exon 9 (58%), KIT exon 11 (34%), and wild-type KIT/PDGFRA (56%). Here, KIT is linked to gastrointestinal stromal tumor.